No Data
No Data
Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Eli Lilly (LLY) will buy biopharmaceutical company Morphic (MORF) for roughly $3.2 billion in a bid to expand its immunology portfolio with oral therapies targeting cell proteins for chronic diseases.
Express News | RBC Capital Downgrades Morphic Holding to Sector Perform, Lowers Price Target to $57
Morphic Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 1.42% RBC Capital $70 → $57 Downgrades Outperform → Sector Perform 03/08/2024 17.44%
TD Cowen Downgrades Morphic Holding to Hold From Buy
Morphic Holding (MORF) has an average rating of outperform and price targets ranging from $30 to $64, according to analysts polled by Capital IQ.Price: 55.80, Change: +0.06, Percent Change: +0.11
Morphic Holding Acquisition Prospects: A Balanced Hold Rating Amid Lilly's Offer and Pipeline Potential
Express News | Morphic Holding Inc : BMO Raises Target Price to $57 From $52